Relay Therapeutics prices $200M public offering of common stock at $7.00/share

Relay Therapeutics, Inc.

Public offering of 28.57M shares at $7.00/share; gross proceeds ~$200M.
Net proceeds estimated at ~$189.5M after underwriting discounts and expenses.
Underwriters granted 30-day option to purchase up to an additional 4.29M shares.
Offering expected to close on September 12, 2024; lead managers include Goldman Sachs, TD Cowen, Stifel, BofA Securities.
All shares sold by the company; proceeds will support clinical-stage precision medicine programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.